BLTE Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of -- compared to Belite Bio, Inc.'s net margin of -82.06%. Belite Bio, Inc.'s return on equity of -37.13% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Belite Bio, Inc. has a consensus price target of $184.33, signalling upside risk potential of 22.89%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.64%. Given that Belite Bio, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Belite Bio, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Belite Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Belite Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Belite Bio, Inc. quarterly revenues are --, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Belite Bio, Inc.'s net income of -$21.7M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Belite Bio, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio, Inc. is -- versus 13.91x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

INVO Fertility, Inc. has a net margin of -- compared to Belite Bio, Inc.'s net margin of -150.51%. Belite Bio, Inc.'s return on equity of -37.13% beat INVO Fertility, Inc.'s return on equity of -471.28%.

Belite Bio, Inc. has a consensus price target of $184.33, signalling upside risk potential of 22.89%. On the other hand INVO Fertility, Inc. has an analysts' consensus of -- which suggests that it could grow by 9250.65%. Given that INVO Fertility, Inc. has higher upside potential than Belite Bio, Inc., analysts believe INVO Fertility, Inc. is more attractive than Belite Bio, Inc..

Belite Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison INVO Fertility, Inc. has a beta of 2.540, suggesting its more volatile than the S&P 500 by 153.97%.

Belite Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INVO Fertility, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio, Inc. pays -- of its earnings as a dividend. INVO Fertility, Inc. pays out -- of its earnings as a dividend.

Belite Bio, Inc. quarterly revenues are --, which are smaller than INVO Fertility, Inc. quarterly revenues of $1.8M. Belite Bio, Inc.'s net income of -$21.7M is lower than INVO Fertility, Inc.'s net income of -$2.6M. Notably, Belite Bio, Inc.'s price-to-earnings ratio is -- while INVO Fertility, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio, Inc. is -- versus 0.03x for INVO Fertility, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Janux Therapeutics, Inc. has a net margin of -- compared to Belite Bio, Inc.'s net margin of -243.13%. Belite Bio, Inc.'s return on equity of -37.13% beat Janux Therapeutics, Inc.'s return on equity of -10.94%.

Belite Bio, Inc. has a consensus price target of $184.33, signalling upside risk potential of 22.89%. On the other hand Janux Therapeutics, Inc. has an analysts' consensus of $66.24 which suggests that it could grow by 301.18%. Given that Janux Therapeutics, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Janux Therapeutics, Inc. is more attractive than Belite Bio, Inc..

Belite Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Janux Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Belite Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Janux Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio, Inc. pays -- of its earnings as a dividend. Janux Therapeutics, Inc. pays out -- of its earnings as a dividend.

Belite Bio, Inc. quarterly revenues are --, which are smaller than Janux Therapeutics, Inc. quarterly revenues of $10M. Belite Bio, Inc.'s net income of -$21.7M is higher than Janux Therapeutics, Inc.'s net income of -$24.3M. Notably, Belite Bio, Inc.'s price-to-earnings ratio is -- while Janux Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio, Inc. is -- versus 100.11x for Janux Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen, Inc. has a net margin of -- compared to Belite Bio, Inc.'s net margin of -1144.46%. Belite Bio, Inc.'s return on equity of -37.13% beat Ocugen, Inc.'s return on equity of -345.08%.

Belite Bio, Inc. has a consensus price target of $184.33, signalling upside risk potential of 22.89%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 637.71%. Given that Ocugen, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Ocugen, Inc. is more attractive than Belite Bio, Inc..

Belite Bio, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 4.540, suggesting its more volatile than the S&P 500 by 354.007%.

Belite Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Belite Bio, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.

Belite Bio, Inc. quarterly revenues are --, which are smaller than Ocugen, Inc. quarterly revenues of $1.8M. Belite Bio, Inc.'s net income of -$21.7M is lower than Ocugen, Inc.'s net income of -$20.1M. Notably, Belite Bio, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Belite Bio, Inc. is -- versus 66.96x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.